The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas
Open accessAbstract
This single-institution phase II study was performed to estimate the response rate to lapatinib in neurofibromatosis type 2 (NF2) patients with progressive vestibular schwannoma (VS). Twenty-one eligible patients were enrolled. Brain and spine MRIs, including 3-dimensional volumetric tumor analysis, and audiograms were performed once at baseline and again every 12 weeks. The primary response end point was evaluable in 17 patients and defined as ≥15% decrease in VS volume. Hearing was evaluable as a secondary end point in 13 patients, with responses defined as an improvement in the pure tone average of at least 10 dB or a statistically significant increase in word recognition scores. Four of 17 evaluable patients experienced an objective volumetric response (23.5%; 95% confidence interval [CI], 10%-47%), with median time to response of 4.5 months (range, 3-12). In responders, reduction in VS volumes ranged from -15.7% to -23.9%. Four of 13 patients evaluable for hearing met hearing criteria for response (30.8%; 95% CI, 13%-58%). One sustained response exceeded 9 months in duration. Median time to overall progression (ie, volumetric progression or hearing loss) was 14 months. The estimated overall progression-free survival and volumetric progression-free survival at 12 months were 64.2% (95% CI, 36.9%-82.1%) and 70.6% (95% CI, 43.1%-86.6%), respectively. Toxicity was generally minor, and no permanent dose modifications were required. Lapatinib carries minor toxicity and has objective activity in NF2 patients with progressive VS, including volumetric and hearing responses. Future studies could explore combination therapy with other molecular targeted agents such as bevacizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Qian, X., Karpova, T., Sheppard, A. M., McNally, J., & Lowy, D. R. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600136 · Cited by 396
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin
Curto, M., Cole, B. K., Lallemand, D., Liu, C.-H., & McClatchey, A. I. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703010 · Cited by 363
Cited by
Schwannomas and Their Pathogenesis
Hilton, D. A., & Hanemann, C. O. (2014) · Brain Pathology · doi:10.1111/bpa.12125 · Cited by 309
Metadata
- Authors
- Karajannis, M. A., Legault, G., Hagiwara, M., Ballas, M. S., Brown, K., Nusbaum, A. O., Hochman, T., Goldberg, J. D., Koch, K. M., Golfinos, J. G., Roland, J. T., & Allen, J. C.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-27
- Volume
- 14
- Issue
- 9
- Pages
- 1163-1170
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2130676729
- Cited by
- 182
- References
- 3
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. https://app.cochat.ai/papers/10.1093/neuonc/nos146
- The paper
- Karajannis, M. A., Legault, G., Hagiwara, M., Ballas, M. S., Brown, K., Nusbaum, A. O., Hochman, T., Goldberg, J. D., Koch, K. M., Golfinos, J. G., Roland, J. T., & Allen, J. C. (2012). Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/nos146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.